Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.
about
Targeted therapies in sarcomas: challenging the challengeDermatofibrosarcoma protuberans: from translocation to targeted therapyFunctional Characterization of Germline Mutations in PDGFB and PDGFRB in Primary Familial Brain CalcificationCore-shell hydrogel particles harvest, concentrate and preserve labile low abundance biomarkersGenetic aberrations in imatinib-resistant dermatofibrosarcoma protuberans revealed by whole genome sequencingRole of platelet-derived growth factors in physiology and medicineThe evolution of systemic therapy in sarcoma.A Review of the Global Guidelines on Surgical Margins for Nonmelanoma Skin Cancers.Imatinib: a breakthrough of targeted therapy in cancer.Nanoparticle technology: addressing the fundamental roadblocks to protein biomarker discoveryTargeting the PDGF signaling pathway in tumor treatmentImatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials.Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.Recurrent dermatofibrosarcoma protuberans over anterior abdominal wall.Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection.Dermatofibrosarcoma protuberans (DFSP): predictors of recurrence and the use of systemic therapy.Molecular diagnosis of dermatofibrosarcoma protuberans: a comparison between reverse transcriptase-polymerase chain reaction and fluorescence in situ hybridization methodologies.SEOM clinical guidelines for the management of adult soft tissue sarcomas.Current treatment options for dermatofibrosarcoma protuberans.Pediatric soft tissue sarcomas.CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans.Sunitinib for patients with locally advanced or distantly metastatic dermatofibrosarcoma protuberans but resistant to imatinib.Phase I/II Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers.New sources of drugs for hematologic malignanciesAdvances in sarcoma genomics and new therapeutic targets.Target therapy of unresectable or metastatic dermatofibrosarcoma protuberans with imatinib mesylate: an analysis on 22 Chinese patients.Dermatofibrosarcoma Protu-Berans with Lung Metastasis Requiring Pneumonectomy.Atrophic dermatofibrosarcoma protuberans: report of a case demonstrated by detecting COL1A1-PDGFB rearrangement.Clinical relevance of molecular genetics to paediatric sarcomasTargeted therapies for soft-tissue sarcomas.Molecular targeted therapies in non-GIST soft tissue sarcomas: what the radiologist needs to knowSpectrum of activity and mechanism of action of VEGF/PDGF inhibitors.Future options for imatinib mesilate-resistant tumors.Combined modalities approach for localized adult extremity soft-tissue sarcoma.Therapeutic potential of directed tyrosine kinase inhibitor therapy in sarcomas.Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.Imatinib as effective therapy for dermatofibrosarcoma protuberans: proof of concept of the autocrine hypothesis for cancer.Targeted therapy of cancer: new roles for pathologists in identifying GISTs and other sarcomas.Role of chemotherapy in pediatric nonrhabdomyosarcoma soft-tissue sarcomas.Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.
P2860
Q21285014-BEFF7799-777B-4B6C-A2E4-6EB0C75B965FQ26771387-C504834D-9077-4777-A78E-2A92A64E1502Q27340260-4279AB4A-6990-4357-9FDE-BB1D7C028DBAQ28474977-B8B29D25-6350-4E4D-A3CB-0AFC1890A0DAQ28534967-DB43A282-9B3D-4407-BD57-A2C41E0A9C3CQ29615222-C3AB0F52-17D0-4B1E-89AB-085152DDAD6BQ33274710-DEEA6665-2B06-4416-865E-2CCECC28AD8FQ33602447-D676D18E-C0DC-4390-B5B8-15C0C991C23CQ33747261-EBECE678-E720-43FC-BBFD-27C4C8CAD0E0Q33862871-89C2A695-1D38-419E-AC21-4D7A65E91FEFQ34393461-20FDF429-1483-47A9-91FD-BC706717F3C2Q34578454-BF36B8AA-75BD-46F0-82CE-B6707A8AA1EAQ34607838-E7DB59E5-64AB-46A0-BDF7-B53B47AC3FF5Q34619519-76C9F466-E952-4C0E-88E9-F7D229BE678DQ34620856-F7C65D19-5FA0-4138-B1A7-1D871047978FQ34623490-8969A432-0BEF-4983-BBAD-29ED994D9568Q34628417-ED1FC83D-8732-405B-B964-7775FDE50F2AQ34639506-81EF7044-FCA6-47C5-A225-A4282978B7DAQ34670080-2D0E7495-C729-4677-BC8A-509B279619BFQ34754962-C894B2BB-6301-49CD-AD7C-B2BB7E5AF5CCQ35691269-B396D3B5-5041-431F-8426-E80D451CA88CQ35871185-9B83DE0C-A30E-4826-96BE-6691E7B2DA2DQ35915719-1693D47A-799B-4790-9298-9F7446350189Q35979113-AE3490AD-9E49-417E-8C4E-CDC761106B8FQ35993346-DA272FAC-2446-4DD8-B165-C8CCDB8711DBQ36153797-36D02AC7-D12B-45DA-87D6-1AFAA3F93B3BQ36438216-A4C84C07-5134-4EA7-BE1F-29632D98A3B7Q36517427-CB45310E-835B-46D9-9EDB-53BC1FB7C80BQ36806186-95749D06-58F4-4C28-975D-36FED05D6ED1Q36817135-B941A695-E025-4D5F-BDAE-2651D0529FDCQ36819466-FE102B23-2A4F-4174-AE3E-935AC6EF13B1Q36872284-01CC586E-EE89-4C05-B46E-A351910CC287Q36964688-74855494-8347-4A7D-9F30-990FD4802BB6Q37008868-F08B08F1-8151-4372-A5C1-9844D4A09F5AQ37038356-5FB290E5-63B8-4285-994E-8059E00E2232Q37109503-C4F7CC8A-B88D-41B1-AE44-E41E2A80D55CQ37137002-8E1C5ECA-4154-4F48-B2A5-83D4E4BC6A57Q37147765-E6D62EB1-FEEB-4373-875B-E344A357197CQ37183459-0555C8EC-9610-4094-976C-5EB6A1D45B90Q37278365-EA861911-9522-4FDA-BC4C-D22B51B41C88
P2860
Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.
description
2005 nî lūn-bûn
@nan
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Molecular and clinical analysi ...... ration Consortium Study B2225.
@ast
Molecular and clinical analysi ...... ration Consortium Study B2225.
@en
Molecular and clinical analysi ...... ration Consortium Study B2225.
@nl
type
label
Molecular and clinical analysi ...... ration Consortium Study B2225.
@ast
Molecular and clinical analysi ...... ration Consortium Study B2225.
@en
Molecular and clinical analysi ...... ration Consortium Study B2225.
@nl
prefLabel
Molecular and clinical analysi ...... ration Consortium Study B2225.
@ast
Molecular and clinical analysi ...... ration Consortium Study B2225.
@en
Molecular and clinical analysi ...... ration Consortium Study B2225.
@nl
P2093
P50
P356
P1476
Molecular and clinical analysi ...... ration Consortium Study B2225.
@en
P2093
Allan van Oosterom
Christopher L Corless
George D Demetri
Jonathan A Fletcher
Sasa Dimitrijevic
Zariana Nikolova
P304
P356
10.1200/JCO.2005.07.088
P407
P577
2005-02-01T00:00:00Z